Unique ID issued by UMIN | UMIN000002488 |
---|---|
Receipt number | R000003029 |
Scientific Title | A randomized controlled trial of stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) for small hepatocellular carcinoma |
Date of disclosure of the study information | 2009/09/16 |
Last modified on | 2015/03/14 16:00:26 |
A randomized controlled trial of stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) for small hepatocellular carcinoma
A randomized controlled trial of SBRT with RFA for small hepatocellular carcinoma
A randomized controlled trial of stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) for small hepatocellular carcinoma
A randomized controlled trial of SBRT with RFA for small hepatocellular carcinoma
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic medicine | Radiology |
Malignancy
NO
To compare the efficacy and safety of stereotactic body radiation therapy with those of radiofrequency ablation in the treatment of small hepatocellular carcinoma
Safety,Efficacy
Confirmatory
Pragmatic
Phase III
Three-year survival
Three-year local tumor control rate
Incidence of adverse events
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Central registration
2
Treatment
Device,equipment | Maneuver |
Stereotactic body radiation therapy
A total dose of 48 Gy is planned in 4 fractions over 4-8 days
Percutaneous radiofrequency ablation
One procedure per week, one or more procedures will be performed
20 | years-old | <= |
Not applicable |
Male and Female
(1) Histopathologically confirmed carcinoma or a lesion showing characteristic features of hepatocellular carcinoma (HCC) on dynamic CT imaging
(2) Either a single lesion 5 cm or less in diameter, or two lesions each 3 cm or less in diameter
(3) Ineligibility for surgical resection or transplantation, or refusal to undergo surgical resection or transplantation
(4) No vascular invasion and no extrahepatic metastasis
(5) Liver function of Child-Pugh class A
(6) Platelet count more than 50000 per cubic millimeter
(7) Prothrombin time ratio (ie, normal time divided by patient's time) greater than 50%
(8) ECOG performance status (PS) of 0 or 1
(1) Active infectious disease requiring treatment
(2) In pregnancy or lactation, or with expectation of pregnancy
(3) History of irradiation to body trunk for any disease
(4) Implantation of a permanent pacemaker
(5) Tumors abutting the stomach or intestinal loop
(6) Simultaneous malignancies
288
1st name | |
Middle name | |
Last name | Shinji Katsushima |
National Hospital Organization
Kyoto Medical Center
Department of Gastroenterology
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, JAPAN
075-641-9161
skatsush@kyotolan.hosp.go.jp
1st name | |
Middle name | |
Last name | Shinji Katsushima |
National Hospital Organization Kyoto Medical Center
Department of Gastroenterology
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, JAPAN
075-641-9161
skatsush@kyotolan.hosp.go.jp
Department of Gastroenterology,
National Hospital Organization,
Kyoto Medical Center
None
Self funding
JAPAN
NO
独立行政法人国立病院機構京都医療センター(京都府)
2009 | Year | 09 | Month | 16 | Day |
Unpublished
Completed
2009 | Year | 08 | Month | 19 | Day |
2009 | Year | 09 | Month | 01 | Day |
2018 | Year | 08 | Month | 01 | Day |
2009 | Year | 09 | Month | 14 | Day |
2015 | Year | 03 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003029